Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 19, 2023 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 31,572 | -- | 560,638 | |
| Jul 25, 2014 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 30,884 | -- | 185,174 | |
| Jul 19, 2023 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,242 | -- | -- | |
| Jul 19, 2023 | EVP and CFO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,242 | -- | -- | |
| Jul 14, 2020 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 30,242 | -- | 30,242 | |
| Jul 12, 2019 | SVP/GM, Global Vascular | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,000 | -- | -- | |
| Jul 19, 2023 | SVP International | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 29,322 | -- | 29,322 | |
| Jul 19, 2023 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 28,691 | -- | 115,979 | |
| Jul 19, 2023 | SVP International | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 28,336 | -- | 28,336 | |
| Jul 22, 2015 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 28,061 | -- | 207,241 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.